HC Wainwright Has Lowered Expectations for MediWound (NASDAQ:MDWD) Stock Price

MediWound (NASDAQ:MDWD) had its target price cut by investment analysts at HC Wainwright from $28.00 to $25.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 43.27% from the company’s previous close.

Separately, StockNews.com raised MediWound to a “sell” rating in a report on Monday, August 5th.

MediWound Trading Up 3.3 %

NASDAQ MDWD opened at $17.45 on Wednesday. The stock has a market capitalization of $188.29 million, a price-to-earnings ratio of -8.08 and a beta of 0.83. The business’s 50 day moving average is $17.16 and its two-hundred day moving average is $17.38. MediWound has a 12-month low of $8.48 and a 12-month high of $24.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC grew its holdings in shares of MediWound by 311.3% in the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 8,449 shares during the period. State Street Corp boosted its position in MediWound by 219.6% during the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock worth $1,197,000 after purchasing an additional 45,529 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in MediWound in the third quarter valued at $212,000. Investor AB purchased a new position in shares of MediWound in the third quarter valued at $15,750,000. Finally, MetLife Investment Management LLC acquired a new position in shares of MediWound during the 3rd quarter worth $89,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.